Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Depreciation & Amortization (CF) (2016 - 2025)

Traws Pharma (TRAW) has disclosed Depreciation & Amortization (CF) for 14 consecutive years, with $15000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 650.0% to $15000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $19000.0, a 35.71% increase, with the full-year FY2024 number at $12000.0, down 25.0% from a year prior.
  • Depreciation & Amortization (CF) was $15000.0 for Q3 2025 at Traws Pharma, up from $1000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $15000.0 in Q3 2025 to a low of $1000.0 in Q1 2025.
  • A 5-year average of $3842.1 and a median of $4000.0 in 2021 define the central range for Depreciation & Amortization (CF).
  • Biggest YoY gain for Depreciation & Amortization (CF) was 650.0% in 2025; the steepest drop was 75.0% in 2025.
  • Traws Pharma's Depreciation & Amortization (CF) stood at $4000.0 in 2021, then changed by 0.0% to $4000.0 in 2022, then changed by 0.0% to $4000.0 in 2023, then plummeted by 50.0% to $2000.0 in 2024, then skyrocketed by 650.0% to $15000.0 in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Depreciation & Amortization (CF) are $15000.0 (Q3 2025), $1000.0 (Q2 2025), and $1000.0 (Q1 2025).